Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30542564 | 1.00 | TDP1 (0.61) | TDP1L3MBTL1KDM4EPOLBCTDSP1 | |
| SCHEMBL8373474 | 0.93 | TDP1 (0.54) | TDP1L3MBTL1KDM4EPOLBCTDSP1 | |
| SCHEMBL104452 | 0.86 | PKM (0.59) | TDP1L3MBTL1KDM4EPOLBCTDSP1 | |
| SCHEMBL29740471 | 0.86 | PKM (0.59) | TDP1L3MBTL1KDM4EPOLBCTDSP1 | |
| SCHEMBL4869351 | 0.85 | TDP1 (0.50) | TDP1L3MBTL1KDM4EPOLBCTDSP1 | |
| SCHEMBL5792626 | 0.84 | TSHR (0.48) | TDP1L3MBTL1KDM4EPOLBCTDSP1 | |
| SCHEMBL1977244 | 0.83 | HPGD (0.49) | TDP1L3MBTL1KDM4EPOLBCTDSP1 | |
| SCHEMBL2521491 | 0.83 | HPGD (0.52) | TDP1L3MBTL1KDM4EPOLBCTDSP1 | |
| SCHEMBL16955551 | 0.83 | TDP1 (0.50) | TDP1L3MBTL1KDM4EPOLBCTDSP1 | |
| SCHEMBL9747035 | 0.82 | TDP1 (0.56) | TDP1L3MBTL1KDM4EPOLBCTDSP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171447-A1 | ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2025-05-29 | — | — | US | disclosed |
| EP-4479056-A1 | ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE THEREOF | Merck Sharp & Dohme LLC (US) | 2024-12-25 | — | — | EP | disclosed |
| WO-2024127363-A1 | TYK2 PSEUDOKINASE LIGANDS AND USES THEREOF | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2024-06-20 | — | — | WO | disclosed |
| WO-2023158626-A1 | ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-08-24 | — | — | WO | disclosed |
| US-20150173359-A1 | SUBSTITUTED FUSED PYRIMIDINONES AND DIHYDROPYRIMIDINONES | BAYER IP GMBH (DE) | 2015-06-25 | — | — | US | disclosed |
| US-9006265-B2 | Substituted fused pyrimidinones and dihydropyrimidinones | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| EP-2718284-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | Glenmark Pharmaceuticals S.A. (CH) | 2014-04-16 | — | — | EP | disclosed |
| WO-2013186692-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-12-19 | — | — | WO | disclosed |
| EP-2611300-A1 | SUBSTITUTED FUSED PYRIMIDINONES AND DIHYDROPYRIMIDINONES | Bayer Intellectual Property GmbH (DE) | 2013-07-10 | — | — | EP | disclosed |
| US-20120157306-A1 | Substituted Fused Pyrimidinones and Dihydropyrimidinones | BAYER CROPSCIENCE AG (DE) | 2012-06-21 | — | — | US | disclosed |
| EP-0966476-A1 | QUINAZOLINONE COMPOUNDS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1999-12-29 | — | — | EP | disclosed |
| EP-0897915-A1 | QUINAZOLINONE CONPOUNDS AS CHEMOTHERAPEUTIC AGENTS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1999-02-24 | — | — | EP | disclosed |
| WO-1998033802-A1 | QUINAZOLINONE COMPOUNDS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1998-08-06 | — | — | WO | disclosed |
| US-5756510-A | POTENTIATE EFFECTS OF CYTOTOXIC DRUGS OR RADIOTHERAPY | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1998-05-26 | — | — | US | disclosed |
| EP-0628032-B1 | QUINAZOLINONE ANTIANGINAL AGENTS | PFIZER LTD (GB) | 1998-05-13 | — | — | EP | disclosed |
| EP-0749415-A1 | BENZAMIDE ANALOGS, USEFUL AS PARP (ADP-RIBOSYLTRANSFERASE, ADPRT) DNA REPAIR ENZYME INHIBITORS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1996-12-27 | — | — | EP | disclosed |
| US-5482941-A | Quinazolinone antianginal agents | PFIZER INC. (US) | 1996-01-09 | — | — | US | disclosed |
| WO-1995024379-A1 | BENZAMIDE ANALOGS, USEFUL AS PARP (ADP-RIBOSYLTRANSFERASE, ADPRT) DNA REPAIR ENZYME INHIBITORS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1995-09-14 | — | — | WO | disclosed |
| EP-0628032-A1 | QUINAZOLINONE ANTIANGINAL AGENTS | Pfizer Limited (GB) | 1994-12-14 | — | — | EP | disclosed |
| WO-1993012095-A1 | QUINAZOLINONE ANTIANGINAL AGENTS | PFIZER LIMITED (GB) | 1993-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150173359-A1 | SUBSTITUTED FUSED PYRIMIDINONES AND DIHYDROPYRIMIDINONES | DHPS, FDPS, DPYD | TDP1 1983/4885L3MBTL1 3190/4885KDM4E 2891/4885 |
| US-20250171447-A1 | ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE THEREOF | ADORA2A, ADORA2B, ADORA1 | TDP1 2272/4885L3MBTL1 4324/4885KDM4E 3489/4885 |
| US-20120157306-A1 | Substituted Fused Pyrimidinones and Dihydropyrimidinones | DHPS, FDPS, DPYD | TDP1 1983/4885L3MBTL1 3190/4885KDM4E 2891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.